



Department of Health Care Finance



PHARMACY & THERAPEUTICS  
COMMITTEE MEETING

Thursday, June 4<sup>th</sup>, 2026  
Time: 2:00 PM – 5:30 PM

Online Only

**\*Please register at:**

[https://primetherapeutics.zoom.us/webinar/register/WN\\_VP11glumQQm0k9UHQFWIFw](https://primetherapeutics.zoom.us/webinar/register/WN_VP11glumQQm0k9UHQFWIFw)

- |                                       |   |
|---------------------------------------|---|
| 1) Call to Order                      | Charlene Fairfax, RPh   |
| 2) Minutes of Previous Meeting        | Charlene Fairfax, RPh   |
| 3) Comments from Interested Parties** | Gidey Amare, RPh, MS  |
| 4) Clinical Drug Class Reviews        | Zakia Al-Amin, PharmD, BCACP<br>Ron Kavanagh, BS Pharm, PharmD, PhD |

Acne Agents, Topical  
Analgesics, Narcotics Long Acting &  
Tramadol Like agents  
Antibiotics, Inhaled  
Antihistamines, Minimally Sedating  
Antimigraine Agents, Triptans and Others  
Bronchodilators, Beta Agonists  
COPD Agents  
Epinephrine, Self-Injected  
Glucocorticoids, Inhaled  
Immunomodulators, Asthma (*tentative*)  
Intranasal Rhinitis Agents  
Leukotriene Modifiers  
NSAIDs  
Ophthalmic Antibiotics  
Ophthalmic Antibiotic-Steroid Combinations

Ophthalmics for Allergic Conjunctivitis  
Ophthalmics, Anti-Inflammatories  
Ophthalmics, Dry Eye Agents  
Ophthalmics, Glaucoma Agents  
Opiate Dependence Treatments  
Otic Antibiotics  
Otic Anti-Inflammatories  
PAH Agents, Oral and Inhaled  
Potassium Binders  
Skeletal Muscle Relaxants  
Smoking Cessation Agents  
Steroids, Topical High  
Steroids, Topical Low  
Steroids, Topical Medium  
Steroids, Topical Very High  
Stimulants and Related Agents

- |   |  |
|---|--|
| 5) Executive Session (Committee Only)***                                | Charlene Fairfax, RPh<br>MMA Representatives |
| 6) Final Recommendations of Preferred Drugs****<br>Announced at 5:00 PM | MMA Representatives                          |

7) Announcement of Next Scheduled P&T Committee Meeting      Charlene Fairfax, RPh  
Thursday, September 3<sup>rd</sup>, 2026

8) Final Comments and Adjournment      Charlene Fairfax, RPh

- \*    **After registering attendees will receive instructions on how to attend the webinar**
- \*\*   **Individuals making oral presentations to the Committee will be limited to three (3) Minutes and will have to register separately as a presenter**
- \*\*\* **Closed Session**
- \*\*\*\* **Open Session**